ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Preemptive  Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting 

K. M. Doss1, C. Kling1, M. R. Heldman1, N. Singh2, M. Wagener3, C. E. Fisher1, A. Limaye1

1University of Washington, Seattle, WA, 2University of Pittsburgh, PIttsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

Meeting: 2022 American Transplant Congress

Abstract number: 979

Keywords: Cytomeglovirus, High-risk, Prophylaxis, Viral therapy

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) II

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose:  Preemptive therapy  (PET)  has  demonstrated superiority to antiviral prophylaxis  for  prevention of  cytomegalovirus (CMV)  disease  in  CMV  donor seropositive/recipient seronegative (D+R-)  liver transplant recipients  (LTxRs)  in clinical trials. However, logistical challenges may preclude PET implementation  in  clinical practice  and  the feasibility  of PET has  not been assessed  in real-world settings.  

*Methods: We  retrospectively assessed a  cohort of consecutive  adult  CMV D+R- LTxRs  receiving PET for CMV prevention  between 4/4/2019 and 4/18/2021 at a single center (real-world  cohort, N=48) and compared measures of adherence to PET protocols and clinical outcomes to  a cohort of  CMV D+R-  LTxRs   randomized to PET as part of a clinical trial (CAPSIL,  N=100). PET consisted of weekly CMV plasma PCR  for 3 months  post-transplant  with initiation of valganciclovir 900mg twice daily at any detectable level of viremia. Adherence to PET was measured by proportion of  required  CMV PCRs  actually  performed,  proportion  of  patients  with >80% of scheduled  PCRs  completed,  and time to initiation of antivirals  in viremic patients. Clinical outcomes included incidence of CMV disease, allograft rejection, re-transplant and mortality within 6 months of transplant. Chi-square and Fisher’s exact tests were used to compare proportions between groups.   

*Results:  Incidence of viremia was similar in the real-world and CAPSIL cohorts (88% vs  81%, respectively).   There was no significant difference in the proportion of successfully completed  CMV  plasma PCRs  between the real-world (584/686, 85%) and CAPSIL (1207/1313, 92%) cohorts (p=0.28). Antivirals were initiated at a median of 3 days (IQR 2-3.75) in the real-world group versus 2 days (IQR 1-4) in the CAPSIL cohort. CMV  syndrome or end-organ  disease occurred in 8% of real-world  cohort  and 7% of  LTxRs  in the CAPSIL group (p=0.75). There was no significant difference in the incidence of allograft rejection, re-transplantation, or death between groups (Figure  1). 

*Conclusions: Adherence to viral load monitoring and timely initiation of antivirals is feasible in  LTxRs  receiving PET for CMV disease prevention in a real-world setting.  Further research is needed to  assess  the  generalizability  of these findings in  broader  clinical  contexts. 

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Doss KM, Kling C, Heldman MR, Singh N, Wagener M, Fisher CE, Limaye A. Preemptive  Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting  [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/preemptive-therapy-for-cytomegalovirus-cmv-disease-prevention-in-high-risk-cmv-donor-seropositive-recipient-seronegative-d-r-liver-transplant-recipients-in-a-real-world-setting/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences